LGVN logo

LGVN Longeveron Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.92
-0.19 (-9.00%)

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cell…

Market Cap: $5.84Mwww.longeveron.com

Price

No data yet.

Social Signal Score

60
5d
—
30d
60
1 mentions
—
60d
60
2 mentions
—
90d
61
5 mentions
—
news: 5

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 3Hold 1Sell 0Strong Sell 0
Avg price target$10+420.8%
Low $10Median $10High $10
Current Consensus

Revenue

$115.0K-93.76%
$63.0K$663.7K$1.26M$1.86M
Dec 2019Sep 2026

Analyst Estimates

FY2025
$-14.27
$-16.25–$-12.65
2 analysts
FY2026
$-4.29
$-4.89–$-3.80
1 analysts
FY2027
$-5.95
$-6.78–$-5.28
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Stephen H. Willard
Sector
Healthcare
Industry
Biotechnology
Employees
38
Beta
-0.26
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-22.81
www.longeveron.com